Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Cash & Equivalents (2018 - 2025)

10x Genomics' Cash & Equivalents history spans 8 years, with the latest figure at $474.0 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 37.75% year-over-year to $474.0 million; the TTM value through Dec 2025 reached $474.0 million, up 37.75%, while the annual FY2025 figure was $474.0 million, 37.75% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $474.0 million at 10x Genomics, up from $432.5 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $622.0 million in Q2 2021 and bottomed at $219.7 million in Q4 2022.
  • The 5-year median for Cash & Equivalents is $368.2 million (2023), against an average of $397.8 million.
  • The largest annual shift saw Cash & Equivalents surged 83.01% in 2021 before it crashed 62.59% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $587.4 million in 2021, then plummeted by 62.59% to $219.7 million in 2022, then skyrocketed by 63.5% to $359.3 million in 2023, then dropped by 4.24% to $344.1 million in 2024, then surged by 37.75% to $474.0 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Cash & Equivalents are $474.0 million (Q4 2025), $432.5 million (Q3 2025), and $397.7 million (Q2 2025).